Alkermes plc (ALKS) Announces Third ALKS 5461 Phase 3 Met Primary Endpoint in MDD – StreetInsider.com
CNBC |
Alkermes plc (ALKS) Announces Third ALKS 5461 Phase 3 Met Primary Endpoint in MDD
StreetInsider.com Alkermes plc (NASDAQ: ALKS) announced positive topline results from FORWARD-5, the third phase 3 efficacy study to read out from the FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action … Benzinga's Volume MoversBenzinga Alkermes Depression Candidate Positive in Phase III StudyZacks.com |